Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | EMERALD-1 trial in HCC

Bruno Sangro • 3 Jul 2020
ESMO WCGIC 2020
Gastrointestinal Cancer Liver Cancer Antibodies Bevacizumab Durvalumab Sorafenib
EMERALD-1

Bruno Sangro, MD, PhD, of Clinica Universidad de Navarra, Navarra, Spain, discusses results from the Phase III EMERALD-1 study (NCT03778957) which aimed to characterize transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma (HCC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Bruno Sangro

7:47
Combination tremelimumab and durvalumab in HCC
Bruno Sangro • 30 Jun 2020
5:49
Updates from CheckMate 459
Bruno Sangro • 30 Jun 2020
2:25
Impact of COVID-19 on HCC management
Bruno Sangro • 1 Jul 2020

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals